Patents Assigned to Kaohsiung Medical University
  • Composition and method for treating atherosclerosis, method for determining if a subject has atherosclerosis and method of screening an anti-atherosclerotic drug
    Patent number: 8354520
    Abstract: The invention provides a method for determining if a subject has atherosclerosis, including: determining an endogenous microRNA-195 expression level of a subject suspected of having atherosclerosis; and comparing the endogenous microRNA-195 expression level of the subject with an endogenous microRNA-195 expression level of a normal group, wherein an increase in the endogenous microRNA-195 expression level of the subject as compared to the endogenous microRNA-195 expression level of the normal group indicates that the subject has atherosclerosis.
    Type: Grant
    Filed: December 10, 2009
    Date of Patent: January 15, 2013
    Assignee: Kaohsiung Medical University
    Inventors: Suh-Hang Hank Juo, Yung-Song Wang
  • CHEMICAL PROFILE OF DETECTING BIOACTIVE COMPONENTS OF QUINONES, STILBENES, FLAVONES AND ALKALOIDS
    Publication number: 20130000389
    Abstract: Disclosed are a method for analyzing chemical profiles of components from a herbal medicine product. Components may include quinone (including rhein, sennoside A and/or aloe-emodin), stilbene containing resveratroloside, flavone including baicalin, and/or alkaloid including berberine and/or palmatine. The method includes steps of: (a) respectively chromatographing a methanol extract of product and standard(s) corresponding to the component(s) using HPLC; (b) comparing HPLC chromatogram of extract and standard(s); and (c) analyzing the chemical profiles of the product from the comparison results.
    Type: Application
    Filed: June 20, 2012
    Publication date: January 3, 2013
    Applicant: KAOHSIUNG MEDICAL UNIVERSITY
    Inventors: FANG-RONG CHANG, TUNG-YING WU, YANG-CHANG WU
  • MICRORNA-BASED METHOD FOR ANTI-COLORECTAL CANCER EFFECTS AND PROGNOSIS OF COLORECTAL CANCER
    Publication number: 20120329853
    Abstract: The present invention discloses a method of providing anti-oncogenic effects in a subject suffered from colorectal cancer. The present invention also discloses a method for screening an anti-colorectal cancer agent. The present invention further discloses a method of determining the prognosis of a subject with colorectal cancer.
    Type: Application
    Filed: June 22, 2011
    Publication date: December 27, 2012
    Applicant: KAOHSIUNG MEDICAL UNIVERSITY
    Inventors: SUH-HANG HANK JUO, JAW-YUAN WANG, I-PING YANG, HSIANG-LIN TSAI
  • PROCESSES FOR PREPARING AMINE SALTS OF KMUP-3 AND USE THEREOF
    Publication number: 20120321584
    Abstract: An inhibiting heart failure disease pharmaceutical composition is provided. The pharmaceutical composition includes: an effective amount of a KMUP-3 amine salt of formula (I); wherein RX contains a carboxylic group donated from one selected from a group consisting of a sodium carboxyl methylcellulose (sodium CMC), a ?-polyglutamic acid derivative, and co-polymer salt; RX? is an anion form of the carboxylic group; and a pharmaceutically accepted carrier.
    Type: Application
    Filed: January 23, 2012
    Publication date: December 20, 2012
    Applicant: KAOHSIUNG MEDICAL UNIVERSITY
    Inventor: Ing-Jun Chen
  • Implant surface treatment method having tissues integrated
    Patent number: 8329464
    Abstract: The present disclosure uses different kinds of surface treatment processes on titanium-made dental implants. The growth and attachment conditions of bone cells (MC3T3-E), fibroblasts (NIH 3T3) and epidermal cells (XB-2) on the metal surface of titanium slices with different surface treatments are observed. Tetra-calcium phosphate is used to perform secondary sand-blasting process to clean up the metal surface and provide calcium ions for osteoblastoma physiology. Thus, by adjusting the cells adhesive and proliferative abilities, the success rate of the clinical applications in dental implant is improved.
    Type: Grant
    Filed: September 1, 2010
    Date of Patent: December 11, 2012
    Assignee: Kaohsiung Medical University
    Inventors: Wen-Cheng Chen, Chun-Cheng Hung, Chia-Ling Ko
  • 18?-glycyrrhetinic acid derivatives and synthetic method thereof
    Patent number: 8329940
    Abstract: The present invention provides a chemical compound having the structure being one selected from a group consisting of wherein R1 is one selected from a group consisting of COOCH3, COOCH2Ph, CONHCH(CH3)2 and CONHC6H5, R2 is one selected from a group consisting of H, CH3 and CH(CH3)2, R3 is one selected from a group consisting of H, CH3, CH(CH3)2 and CH2Ph, and R4 is one of CH(CH3)2 and C6H5.
    Type: Grant
    Filed: December 30, 2009
    Date of Patent: December 11, 2012
    Assignee: Kaohsiung Medical University
    Inventors: Chun-Nan Lin, Dravidum Maitraie, Jih-Pyang Wang, Chi-Feng Hung, Huang-Yao Tu, Ya-Ting Liou, Bai-Luh Wei, Shyh-Chyun Yang
  • SYNTHESIS AND ANTITUMOR ACTIVITY OF NOVEL BIS(BENZYLIDENE-BENZENAMINE)DISULFIDES
    Publication number: 20120283475
    Abstract: Novel synthetic bis(benzylidene-benzenamine)disulfides and the preparation method are disclosed in the present invention. These compounds are afforded with the oxidizing reagent at low temperature and short time period via intra-molecular coupling reaction. In vitro experiments have been revealed that bis-disulfides are cytotoxic to cancer cells, especially human breast cancer cells MCF-7. Additionally, bis-disulfides arrest the cell cycle at sub-G1 phase and increase p38 phosphorylation to result in apoptosis. Bis-disulfides also inhibit growth of murine melanoma B16 cells but have no cytotoxicity to human fibroblasts. Bis-disulfides also can reduce murine melanoma size in the mouse model. The prepared compounds of the invention would be applicable in anti-cancer and anti-tumor therapies.
    Type: Application
    Filed: July 26, 2011
    Publication date: November 8, 2012
    Applicant: KAOHSIUNG MEDICAL UNIVERSITY
    Inventors: JEH-JENG WANG, WAN-PING HU, WEI-SHENG LO
  • CONFORMATIONS OF DIVERGENT PEPTIDES WITH MINERAL BINDING AFFINITY
    Publication number: 20120270811
    Abstract: A series of peptides with divergent confirmations including structures of formula (1A), (1B), (2) and (3) are provided. In the formula, wherein U, G, A, B, R1, R2 and T are as defined in the specification. The divergent peptides disclosed in the present invention are characterized in a mineral binding affinity function.
    Type: Application
    Filed: October 21, 2011
    Publication date: October 25, 2012
    Applicant: KAOHSIUNG MEDICAL UNIVERSITY
    Inventors: Hui-Ting Chen, Kuang-Chan Hsieh, Je-Ken Chang, Gwo-Jaw Wang, Yin-Chih Fu, Mei-Ling Ho, Cherng-Chyi Tzeng
  • CHONDROITIN SULFATE-POLYCAPROLACTONE COPOLYMER, METHOD FOR PREPARING THE SAME AND APPLICATION THEREOF
    Publication number: 20120264830
    Abstract: A method for preparing a chondroitin sulfate-polycaprolactone copolymer includes subjecting a chondroitin sulfate component and a polycaprolactone polymer to an atom transfer radical polymerization reaction in the presence of a catalyst.
    Type: Application
    Filed: December 15, 2011
    Publication date: October 18, 2012
    Applicant: KAOHSIUNG MEDICAL UNIVERSITY
    Inventors: Li-Fang Wang, Yu-Sheng LIU
  • BIOACTIVITY COMPOSITION OF Reevesia formosana
    Publication number: 20120258923
    Abstract: A series cardenolide derivatives including structure of formula I from the root of Reevesia formosana have provided. In formula (1) and (2), where R3, R5, R10 and R16 are as defined in the specification. The derivatives compounds showed potent cytotoxicity against MCF-7, NCI-H460, and HepG2 cancer cell lines.
    Type: Application
    Filed: October 4, 2011
    Publication date: October 11, 2012
    Applicant: KAOHSIUNG MEDICAL UNIVERSITY
    Inventors: Ih-Sheng Chen, Hsun-Shuo Chang
  • USE FOR IMPROVING 5-HT FUNCTION AND ENOS EXPRESSION OF KMUPS AMINE SALTS
    Publication number: 20120251482
    Abstract: The synthesized piperazium salt of KMUPs disclosed in the present invention is characterized by presented pharmaceutics having functions to improve 5-HT function and eNOS expression of KMUPS in lung diseases, such as proliferation, obliteration, pulmonary artery hypertension. The pharmaceutical composition for inhibiting monocrotaline (MCT)-induced proliferation of pulmonary artery includes an effective amount of a complex salt of formula (I): wherein R2 and R4 are each selected independently from the group consisting of a C1˜C5 alkoxy group, a hydrogen, a nitro group, and a halogen atom; RX contains a carboxylic group donated from one selected from a group consisting of a Statin, a Co-polymer, a poly-?-polyglutamic acid (?-PGA) derivative and sodium CMC; and ?RX substituent is an anion of the carboxylic group carrying a negative charge; and a pharmaceutically accepted carrier.
    Type: Application
    Filed: September 19, 2011
    Publication date: October 4, 2012
    Applicant: KAOHSIUNG MEDICAL UNIVERSITY
    Inventor: Ing-Jun Chen
  • METHOD OF MODULATING COMPLEMENT FACTOR B (CFB) EXPRESSION IN CELLS
    Publication number: 20120245108
    Abstract: The present invention relates to a method of modulating complement factor B (CFB) expression in cells, comprising administering an effective amount of tannic acid to the cells. This method can be applied in treating or prophylaxis of the disease, disorder or medical condition associated to complement factor B (CFB) expression.
    Type: Application
    Filed: March 23, 2011
    Publication date: September 27, 2012
    Applicant: KAOHSIUNG MEDICAL UNIVERSITY
    Inventors: Suh-Hang Hank Juo, Wen-Wen Chou, Jing-Mei Wu, Chung-Ling Liang
  • Indolo[3,2-]quinoline compounds
    Patent number: 8273760
    Abstract: Disclosed herein are indolo[3,2-c]quinoline compounds of formula (I): or a pharmaceutically acceptable salt thereof, wherein R and m are given the definitions as set forth in the Specification and Claims. These compounds can be used to inhibit both growth of cancer cells and activity of telomerase.
    Type: Grant
    Filed: August 31, 2009
    Date of Patent: September 25, 2012
    Assignee: Kaohsiung Medical University
    Inventors: Cherng-Chyi Tzeng, Yeh-Long Chen, Jing-Jer Lin, Chih-Ming Lu
  • SYNTHESIS OF 2-(4-AMINOPHENYL) BENZOTHIAZOLE DERIVATIVES AND USE THEREOF
    Publication number: 20120215154
    Abstract: The present invention provides a method of preparing a compound of formula 6 comprising: (a) reacting a compound of formula 1 with a compound of formula 2 to form a compound of formula 3 wherein X of formula 2 is Cl or OH; (b) treating the compound formula 3 with Lawesson's reagent to form a compound of formula 4 (c) reacting a compound of formula 4 with potassium ferricyanide to produce a compound of formula 5 and (d) performing catalytic reduction of nitro group of the compound of formula 5 with palladium on charcoal to generate the compound of formula 6, wherein R1 of formulae 1-6 is H, C1-10 alkyl, C1-10 alkoxy or C1-10 haloalkyl, and R2 of formulae 1-6 is H or C1-10 alkyl.
    Type: Application
    Filed: February 22, 2011
    Publication date: August 23, 2012
    Applicant: KAOHSIUNG MEDICAL UNIVERSITY
    Inventors: Jeh-Jeng Wang, Chao-Cheng Liao, Wan-Ping Hu, Ho-Chuan Shen
  • NONINVASIVE CUTANEOUS BLOOD FLOW ASSESSMENT AS A RESPONSE PREDICTOR FOR VISIBLE LIGHT THERAPY ON SEGMENTAL VITILIGO
    Publication number: 20120215120
    Abstract: Visible light is a treatment option for Segmental Vitiligo (SV), and visible light-induced repigmentation is associated normalization of sympathetic. Currently it is difficult to predict individual patient's response to visible light therapy. Therefore, the present invention uses the Laser Doppler Flowmeter to serve as a response predictor for visible light on treating SV. The present invention recruited 14 Segmental Vitiligo patients for evaluating clinical information. FirstLaser Doppler Flowmeter was used to evaluate the cutaneous blood flow of SV lesion and contralateral normal skin, and then treated them with visible light irradiate, cold-stress, rewarmed, and recorded the change of skin blood flow, finally the patients received regular visible light treatment for 3 months, and patients have a sign of repigmentation after the treatment.
    Type: Application
    Filed: August 22, 2011
    Publication date: August 23, 2012
    Applicant: KAOHSIUNG MEDICAL UNIVERSITY
    Inventors: HSIN-SU YU, CHENG-CHE LAN, WEI-TAI YU
  • POLY(LACTIC-GLYCOLIC)ACID CROSS LINKED ALENDRONATE (PLGA-ALN) A SHORT TERM CONTROLLED RELEASE SYSTEM FOR STEM CELL DIFFERENTIATION AND DRUG DELIVERY
    Publication number: 20120202064
    Abstract: A short term controlled release composition which comprises poly(lactic-co-glycolic acid) cross-linked alendronate (PLGA-ALN) is provided. The PLGA-ALN is constructed into 3D scaffolds (PLGA-ALN-3D) with pores size of 150-300 ?m and average porosity of 85%, or microspheres (PLGA-ALN-M) with 50-100 ?m in diameter. The released alendronate concentration is in the range of 5×10?7 M to 5×10?8 M.
    Type: Application
    Filed: April 13, 2012
    Publication date: August 9, 2012
    Applicant: KAOHSIUNG MEDICAL UNIVERSITY
    Inventors: Mei-Ling Ho, Je-Ken Chang, Rajalakshmanan Eswaramoorthy, Shun-Cheng Wu
  • METHOD FOR DIAGNOSING SPINAL MUSCULAR ATROPHY
    Publication number: 20120196290
    Abstract: A method for diagnosing spinal muscular atrophy is provided. The method includes providing a biological sample of a subject containing a nucleotide of SMN gene, amplifying SMN exons 1, 2a, 2b, 3, 4, 5, 6, 7, and 8 by a universal multiplex PCR using the nucleotide as a template and the primers to obtain fragments of the SMN exons 1, 2a, 2b, 3, 4, 5, 6, 7, and 8, labeling the fragments of the SMN exons 1, 2a, 2b, 3, 4, 5, 6, 7, and 8 by a fluorescent primer to obtain fluorescence-labeled exon fragments, and analyzing the fluorescence-labeled exon fragments by a capillary electrophoresis under a optimized separation condition. If the SMN1/SMN2 ratios in exon 7 and 8 are different, it indicates that the subject is susceptible to spinal muscular atrophy. Additionally, if the peak of certain exon fragment appears crossed, it indicates an intragenic mutation in the exon.
    Type: Application
    Filed: January 27, 2011
    Publication date: August 2, 2012
    Applicant: KAOHSIUNG MEDICAL UNIVERSITY
    Inventors: SHOU-MEI WU, CHUN-CHI WANG, JAN-GOWTH CHANG, YUH-JYH JONG
  • METHOD AND KIT FOR IN VITRO DIAGNOSIS OF ATHEROSCLEROSIS
    Publication number: 20120196293
    Abstract: A method for in vitro diagnosis of atherosclerosis, comprising: (a) obtaining a sample from a subject; (b) determining expression levels of one or more microRNAs (miRNAs) as atherosclerotic biomarkers and an internal control RNA; (c) computing the relative expression levels of the one or more miRNAs as atherosclerotic biomarkers; (d) computing a prediction model with one or more variables, wherein the variable includes one or more relative expression levels of the one or more miRNAs as atherosclerotic biomarkers and one or more risk factors of atherosclerosis; and (e) computing a prediction probability by the prediction model, wherein the subject is diagnosed with atherosclerosis if the probability is more than 0.5 is presented. A kit for in vitro diagnosis of atherosclerosis or prognosis of atherosclerosis-inducing diseases is also presented.
    Type: Application
    Filed: December 22, 2011
    Publication date: August 2, 2012
    Applicant: KAOHSIUNG MEDICAL UNIVERSITY
    Inventors: Suh-Hang Hank Juo, Yung-Song Wang, Pei-Chien Tsai
  • ANTI-BACTERIAL INFECTION, INFLAMMATION, AND LEUKEMIA COMPOSITION AND USE THEREOF
    Publication number: 20120190632
    Abstract: A method of inhibiting the growth of Gram-positive bacteria comprising administering an effective amount of Tellimagrandin II, its pharmaceutically acceptable salt, enantiomer, isomer or tautomer to a subject is provided. The Gram-positive bacteria comprise methicillin-resistant Staphylococcus aureus. A method of treating sepsis comprising administering an effective amount of Tellimagrandin II, its pharmaceutically acceptable salt, enantiomer, isomer or tautomer to a subject is also provided. A method of treating leukemia comprising administering an effective amount of Tellimagrandin II, its pharmaceutically acceptable salt, enantiomer, isomer or tautomer to a subject is further provided.
    Type: Application
    Filed: January 20, 2012
    Publication date: July 26, 2012
    Applicant: KAOHSIUNG MEDICAL UNIVERSITY
    Inventors: Lih-Geeng Chen, Yen-Hsu Chen, Chin Hsu, Hsin-Ju Chien, Shih-Han Kao, Yu-Wei Chang, Wan-Chun Huang
  • TRITERPENOID COMPOSITION OF ANTRODIA CINNAMOMEA, PREPARATION AND ANALYSIS METHOD THEREOF
    Publication number: 20120190871
    Abstract: Disclosed are the isolation, purification and analysis of the triterpenoid compositions (including ergostane and lanostane) in the fruiting body of Antrodia cinnamomea using HPLC and NMR, as well as the stereo structures and the amounts of the triterpenoid compositions. The cytotoxicity of triterpenoids is also revealed. Based on the aforementioned techniques, the presence and amounts of ergostane and lanostane in the drugs, healthcare food or other goods are able to be detected.
    Type: Application
    Filed: January 17, 2012
    Publication date: July 26, 2012
    Applicant: KAOHSIUNG MEDICAL UNIVERSITY
    Inventors: YANG-CHANG WU, FANG-RONG CHANG, MEI-CHIN LU, YING-CHI DU, TUNG-YING WU, YU-MING HSU